ACE-inhibitorer er fortsat førstevalg ved behandling af hjertesvigt--en gennemgang af et Cochranereview

    Abstract

    A new Cochrane metaanalysis has reviewed the literature on the use of angiotensin receptor blockers (ARB) in patients with heart failure and left ventricular systolic dysfunction. The conclusion supports the present recommendation from the European Society of Cardiology that angiotensin converting enzyme inhibitors (ACE-I) are first choice and that ARBs should be reserved to patients who are intolerant to ACE-Is. Neither ACE-Is nor ARBs are effective in the treatment of heart failure patients with normal left ventricular function.
    Bidragets oversatte titelACE inhibitors continue to be first choice in the treatment of heart failure patients
    OriginalsprogDansk
    TidsskriftUgeskrift for Laeger
    Vol/bind175
    Udgave nummer22
    Sider (fra-til)1566-8
    Antal sider3
    ISSN0041-5782
    StatusUdgivet - 27 maj 2013

    Emneord

    • Angiotensin Receptor Antagonists
    • Angiotensin-Converting Enzyme Inhibitors
    • Heart Failure
    • Humans
    • Review Literature as Topic
    • Ventricular Dysfunction, Left

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'ACE-inhibitorer er fortsat førstevalg ved behandling af hjertesvigt--en gennemgang af et Cochranereview'. Sammen danner de et unikt fingeraftryk.

    Citationsformater